IP Library Granted Patent US 7,537,911
Granted Patent B2
US 7,537,911 · App. 11/788,003 · Granted May 26, 2009

ATM related kinase, ATX, nucleic acids encoding same and methods of use

Assignees: Burnham Institute for Medical Research; Duke University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,537,911
App. No.
11/788,003
Granted
May 26, 2009
Kind
B2
Abstract

The invention provides an isolated nucleic acid molecule having substantially the same nucleotide sequence as SEQ ID NO:1. Also provided is an isolated oligonucleotide having at least 15 contiguous nucleotides of a nucleotide sequence referenced as SEQ ID NO:11. An isolated polypeptide having substantially the same amino acid sequence as SEQ ID NO:2 is further provided as well as an antibody, or antigen binding fragment thereof, which specifically binds to an ATX polypeptide and has an amino acid sequence as referenced in SEQ ID NO:2. A method for identifying an ATX-modulatory compound is additionally provided. The method consists of measuring the level of an ATX polypeptide in the presence of a test compound, wherein a difference in the level of said ATX polypeptide in the presence of said test compound compared to in the absence of said test compound indicating that said test compound is an ATX-modulatory compound, and wherein said ATX-modulatory compound is not caffeine or wortmannin.

Claims (6)

1. A method for identifying an ATX-modulatory compound, comprising measuring the level of an ATX polypeptide comprising the amino acid sequence as SEQ ID NO:2 in the presence of a test compound, wherein a difference in the level of that said ATX polypeptide in the presence of said test compound compared to in the absence of that said test compound indicating that said test compound is an ATX-modulatory compound, and wherein said ATX-modulatory compound is not caffeine or wortmannin.

2. The method of claim 1 , wherein said ATX-modulatory compound decreases the level of ATX polypeptide.

3. The method of claim 1 , wherein said ATX-modulatory compound increases the level of ATX polypeptide.

4. The method of claim 1 , wherein said level of ATX polypeptide is measured by determining the kinase activity of said ATX polypeptide.

5. The method of claim 1 , wherein said level of ATX polypeptide is measured by determining the phosphorylation of a mammalian p53 polypeptide or a fragment thereof, comprising a phosphporylation site for the kinase activity of said ATX polypeptide.

6. The method of claim 1 , wherein said level of ATX polypeptide is measured by determining the level of p53 polypeptide accumulation.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 11, 2024
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 067078/0777 →
CHANGE OF NAME Recorded Apr 16, 2009
From: THE BURNHAM INSTITUTE
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 022557/0846 →
Continuity (4)
Division 1164355100 · Dec 20, 2006
Division 1045623800 · Jun 6, 2003
Provisional Application 6081360700 · Jun 6, 2002
Related Publication 20080166713A1 · Jul 10, 2008